Roopal B. Thakkar

Roopal B. Thakkar

Executive Vice President, Research & Development and Chief Scientific OfficeratAbbVie· In the 2025 proxy

Pay in FY2025

Roopal B. Thakkar was paid $9.9M in FY2025 (Dec).

PayNo stock prices for these years
Pay is from the Summary Compensation Table of each AbbVie proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. AbbViePublic company · 1 yr
    • Executive Vice President, Research & Development and Chief Scientific Officer2025 – Present · 1 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?